On the way to a more effective treatment for colorectal cancer
The drug candidate arfolitixorin is designed to improve the efficacy of existing chemotherapy rather than replace it, creating a clear pathway into clinical practice.
Published
Isofol Investor News
Videolängd
1 min
Petter Segelman Lindqvist about TO2
Isofol's CEO Petter Segelman Lindqvist talks about the company's focus and the subscription options of series TO2, where the subscription period runs from November 16–30.
Published
Isofol invites to Investor & Scientific Update
On November 12, an investor meeting in Stockholm will feature Prof. Sebastian Stintzing and Prof. Frits Peters – followed by a summary session in Gothenburg on November 13.
Published
Don't miss the interview at Biostock
BioStock met with CEO Petter Segelman Lindqvist to talk about what is required to proceed to phase II, the license in autism and what the capital from the warrants will be used for.
Published
Highest dose level in phase Ib initiated and phase II approaching
Comment by: Petter Segelman Lindqvist
Additional study sites added to accelerate patient recruitment
Essen University Hospital joins the phase Ib/II arfolitixorin study as a new trial site – expected to provide a significant boost to recruitment ahead of the phase II part.
Published
Highest dose cohort initiated in phase Ib study with arfolitixorin
Following successful evaluation of three dose levels without dose-limiting toxicities, the final dose cohort has now been initiated – moving the study closer to its phase II part.
Published
Isofol and Solasia in Japan Times
Read about the collaboration between Isofol and Solasia in Japan Times appendix Sweden Report.
Published